NCT04361474View on ClinicalTrials.gov

Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity

PHASE3CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

November 24, 2020

Study Completion Date

June 25, 2021

Conditions

BudesonideOlfaction DisordersSARS-CoV-2Anosmia

Interventions

DRUG

Budesonide Nasal

Nasal irrigation with budesonide and physiological saline morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.

OTHER

Physiological serum

Nasal irrigation with physiological saline morning and evening, for 30 days, in addition to olfactory re-education twice a day.

Trial Locations (1)

75019

Amélie YAvchitz, Paris

All Listed Sponsors

collaborator

Hopital Lariboisière

OTHER

lead

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK

NCT04361474 - Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity | Biotech Hunter | Biotech Hunter